Ketamine for Parkinson’s Disease, PharmaTher Holdings Announces Grant of U.S. Patent To Cover It
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a pharmaceutical company focused on developing novel uses and delivery forms of ketamine
PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson’s Disease
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced Friday that the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced dyskinesia in Parkinson’s disease was presented at the MDS
Psychedelic Medicine Co. PharmaTher Provides Update On Pipeline And Milestones For 2022
This article was originally published on Microdose and appears here with permission.
FDA Approves PharmaTher’s Phase 2 Trial For Ketamine ALS Treatment
PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced on Wednesday that the U.S.
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Detroit Decriminalizes Psychedelics
Detroit is the latest to join the growing list of U.S. cities that have decriminalized psychedelic substances.
Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind’s Palliative Care Program
The Week In Psychedelics
Seattle Decriminalizes Psychedelics Along With California City
